CJC-1295 (no DAC) + Ipamorelin common uses, half-life, side effects and more

CJC-1295 (no DAC) and ipamorelin are two growth hormone secretagogues sold together and injected under the skin. The first is Modified GRF 1-29 sold as CJC-1295 no DAC. The second is ipamorelin. People pair them to raise their own growth hormone and IGF-1 without injecting growth hormone itself. The usual goals are recovery, sleep, and body composition. The two are combined because they act on separate pituitary signals and may produce a larger growth hormone pulse together than either alone. Neither is an approved drug anywhere. Both are sold gray-market as research chemicals. No approved product contains the combination.

• Raising growth hormone and IGF-1 without injecting growth hormone
• Recovery and reduced soreness after training
• Deeper and more restful sleep
• Fat loss and lean-mass support
• Countering the age-related decline in growth hormone

Once daily at bedtime or up to three times daily

Common subcutaneous protocols inject 100 mcg of each peptide per dose from a 1:1 premixed vial. The standard starting dose is 100 mcg of each. Experienced users titrate to 200 to 300 mcg of each while watching IGF-1. The most common retail vial holds 5 mg of each peptide for 10 mg total. A larger vial holds 10 mg of each for 20 mg total. A less common vial uses a 1:2 ratio with more ipamorelin than CJC. That label changes the delivered amounts and should not be read as a 1:1 vial. A 200 mcg total dose from a 1:1 vial delivers 100 mcg of each peptide. A 600 mcg total dose delivers 300 mcg of each. The delivered CJC amount runs from the roughly 100 mcg used on its own up to about three times that. The delivered ipamorelin amount lands at or below its own community range of 200 to 300 mcg per dose. Clinics inject once at bedtime and often five nights per week. Forum protocols inject two to three times daily. Cycles run about 8 to 16 weeks with a month off. Some users run it continuously with IGF-1 labs.

• A premixed vial fixes the component ratio and moves both doses together
• Separate vials let the CJC and ipamorelin doses be set independently
• The pair is usually injected together so the two signals reach the pituitary at once
• Protocols avoid food and especially carbohydrate near the injection because they blunt the growth hormone pulse

No pharmacokinetic study of the combination exists. The two peptides clear at different rates. Ipamorelin has a measured human half-life of about 2 hours from an intravenous infusion. No human study has measured the half-life of Modified GRF 1-29. It clears within minutes based on measurements of related analogs.

• Injection-site redness, pain, swelling, or itching
• Flushing, warmth, lightheadedness, headache, or faster heart rate soon after a dose
• Water retention, joint aches, or tingling hands from raising growth hormone
• Higher blood sugar or reduced insulin sensitivity
• Nausea, vomiting, insomnia, or low potassium reported in intravenous ipamorelin trials

• CJC-1295 (no DAC)

  100 to 300 mcg per dose from a 1:1 vial

• Ipamorelin

  100 to 300 mcg per dose from a 1:1 vial

The CJC-1295 no DAC component activates the growth hormone releasing hormone receptor on the pituitary. That signal tells the pituitary to make and release its own growth hormone. The growth hormone then raises IGF-1 from the liver. Ipamorelin activates the ghrelin receptor on the same gland. That second signal drives growth hormone release through a pathway independent of the first receptor. The pairing rests on the idea that two independent signals produce a larger pulse than either one alone. Human work shows that a growth hormone releasing hormone paired with an older releasing peptide can produce a bigger pulse. No published study has tested ipamorelin with a growth hormone releasing hormone analog in people. The rationale is pathway complementarity rather than direct evidence for this pair.

The evidence for the combination is low. No randomized trial, human pharmacokinetic study, animal study, or case series tests the Modified GRF 1-29 plus ipamorelin pair. The strongest supporting evidence is human endocrine work showing that a growth hormone releasing hormone plus an older releasing peptide can raise growth hormone more than either signal alone. Those studies used other releasing peptides rather than ipamorelin. The pairing is therefore an extrapolation from related molecules. Ipamorelin has one human pharmacokinetic study and one failed postoperative ileus trial. Both were given by vein. Modified GRF 1-29 has no published human study of any kind. Community and clinic dosing is consistent enough to describe as practice rather than as trial-validated dosing.

• Both components are named on the WADA prohibited list and are banned in sport at all times
• People with active or prior cancer should avoid it because growth hormone and IGF-1 can support cell growth
• Diabetes, insulin resistance, or high IGF-1 make growth hormone stimulation riskier
• Products sold as CJC-1295 may contain the longer-acting DAC-linked form that lasts about a week instead of minutes
• The FDA cited an intravenous ipamorelin trial with serious adverse events including deaths of uncertain cause and no study has tested the subcutaneous route people inject
• Pregnancy and breastfeeding should avoid this blend because reproductive and lactation data are absent